Risk factors of extraneural spreading in astrocytomas and oligodendrogliomas in donors with gliomas: A systematic review.

Serena Ammendola, Valeria Barresi, Elena Bariani, Ilaria Girolami, Antonia D'Errico, Matteo Brunelli, Massimo Cardillo, Letizia Lombardini, Amedeo Carraro, Ugo Boggi, Owen Cain, Desley Neil, Albino Eccher
{"title":"Risk factors of extraneural spreading in astrocytomas and oligodendrogliomas in donors with gliomas: A systematic review.","authors":"Serena Ammendola,&nbsp;Valeria Barresi,&nbsp;Elena Bariani,&nbsp;Ilaria Girolami,&nbsp;Antonia D'Errico,&nbsp;Matteo Brunelli,&nbsp;Massimo Cardillo,&nbsp;Letizia Lombardini,&nbsp;Amedeo Carraro,&nbsp;Ugo Boggi,&nbsp;Owen Cain,&nbsp;Desley Neil,&nbsp;Albino Eccher","doi":"10.5500/wjt.v12.i6.131","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Patients with a history of primary brain tumors can be eligible for organ donation under extended criteria. The risk assessment of tumor transmission <i>via</i> organ transplant in primary brain tumors is primarily based on the assessment of tumor histotype and grade. Previous surgeries, chemo-/radiotherapy, and ventriculo-peritoneal shunt placement can lead to a disruption of the blood-brain barrier, concurring to an increase in the transmission risk.</p><p><strong>Aim: </strong>To investigate the role of tumor transmission risk factors in donors with oligodendrogliomas and astrocytomas.</p><p><strong>Methods: </strong>We searched PubMed and EMBASE databases for studies reporting extraneural spreading of oligodendrogliomas and astrocytomas and extracted clinical-pathological data on the primary tumor histotype and grade, the elapsed time from the diagnosis to the onset of metastases, sites and number of metastases, prior surgeries, prior radiotherapy and/or chemotherapy, ventriculo-atrial or ventriculo-peritoneal shunt placement, and the presence of isocitrate dehydrogenase 1/2 mutation and 1p/19q codeletion. Statistical analysis was performed using R software. Statistical correlation between chemotherapy or radiotherapy and the presence of multiple extra-central nervous system metastases was analyzed using <i>χ</i> <sup>2</sup> and Fischer exact test. The Kaplan-Meier method was used to evaluate the presence of a correlation between the metastasis-free time and: (1) Localization of metastases; (2) The occurrence of intracranial recurrences; and (3) The occurrence of multiple metastases.</p><p><strong>Results: </strong>Data on a total of 157 patients were retrieved. The time from the initial diagnosis to metastatic spread ranged from 0 to 325 mo in patients with oligodendrogliomas and 0 to 267 mo in those with astrocytomas. Respectively, 19% and 39% of patients with oligodendroglioma and astrocytoma did not receive any adjuvant therapy. The most frequent metastatic sites were bone, bone marrow, and lymph nodes. The lungs and the liver were the most commonly involved visceral sites. There was no significant correlation between the occurrence of multiple metastases and the administration of adjuvant chemo-/radiotherapy. Patients who developed intracranial recurrences/metastases had a significantly longer extraneural metastasis-free time compared to those who developed extraneural metastases in the absence of any intra- central nervous system spread.</p><p><strong>Conclusion: </strong>A long follow-up time does not exclude the presence of extraneural metastases. Therefore, targeted imaging of bones and cervical lymph nodes may improve safety in the management of these donors.</p>","PeriodicalId":68893,"journal":{"name":"世界移植杂志(英文版)","volume":"12 6","pages":"131-141"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/24/49/WJT-12-131.PMC9258267.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"世界移植杂志(英文版)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5500/wjt.v12.i6.131","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Patients with a history of primary brain tumors can be eligible for organ donation under extended criteria. The risk assessment of tumor transmission via organ transplant in primary brain tumors is primarily based on the assessment of tumor histotype and grade. Previous surgeries, chemo-/radiotherapy, and ventriculo-peritoneal shunt placement can lead to a disruption of the blood-brain barrier, concurring to an increase in the transmission risk.

Aim: To investigate the role of tumor transmission risk factors in donors with oligodendrogliomas and astrocytomas.

Methods: We searched PubMed and EMBASE databases for studies reporting extraneural spreading of oligodendrogliomas and astrocytomas and extracted clinical-pathological data on the primary tumor histotype and grade, the elapsed time from the diagnosis to the onset of metastases, sites and number of metastases, prior surgeries, prior radiotherapy and/or chemotherapy, ventriculo-atrial or ventriculo-peritoneal shunt placement, and the presence of isocitrate dehydrogenase 1/2 mutation and 1p/19q codeletion. Statistical analysis was performed using R software. Statistical correlation between chemotherapy or radiotherapy and the presence of multiple extra-central nervous system metastases was analyzed using χ 2 and Fischer exact test. The Kaplan-Meier method was used to evaluate the presence of a correlation between the metastasis-free time and: (1) Localization of metastases; (2) The occurrence of intracranial recurrences; and (3) The occurrence of multiple metastases.

Results: Data on a total of 157 patients were retrieved. The time from the initial diagnosis to metastatic spread ranged from 0 to 325 mo in patients with oligodendrogliomas and 0 to 267 mo in those with astrocytomas. Respectively, 19% and 39% of patients with oligodendroglioma and astrocytoma did not receive any adjuvant therapy. The most frequent metastatic sites were bone, bone marrow, and lymph nodes. The lungs and the liver were the most commonly involved visceral sites. There was no significant correlation between the occurrence of multiple metastases and the administration of adjuvant chemo-/radiotherapy. Patients who developed intracranial recurrences/metastases had a significantly longer extraneural metastasis-free time compared to those who developed extraneural metastases in the absence of any intra- central nervous system spread.

Conclusion: A long follow-up time does not exclude the presence of extraneural metastases. Therefore, targeted imaging of bones and cervical lymph nodes may improve safety in the management of these donors.

Abstract Image

Abstract Image

Abstract Image

神经胶质瘤供体中星形细胞瘤和少突胶质细胞瘤神经外扩散的危险因素:一项系统综述。
背景:有原发性脑肿瘤病史的患者可以在扩展标准下有资格进行器官捐赠。原发性脑肿瘤通过器官移植传播的风险评估主要基于肿瘤的组织类型和分级评估。先前的手术、化疗/放疗和脑室-腹膜分流术可导致血脑屏障的破坏,从而增加传播风险。目的:探讨肿瘤传播危险因素在供体少突胶质细胞瘤和星形细胞瘤中的作用。方法:我们检索了PubMed和EMBASE数据库中关于少突胶质细胞瘤和星形细胞瘤神经外扩散的研究报告,并提取了原发肿瘤的组织类型和分级、从诊断到转移发生的时间、转移的部位和数量、既往手术、既往放疗和/或化疗、脑室-心房或脑室-腹膜分流器放置、异柠檬酸脱氢酶1/2突变和1p/19q密码缺失的临床病理数据。采用R软件进行统计分析。采用χ 2和Fischer精确检验分析化疗或放疗与多发中枢外神经系统转移的统计学相关性。采用Kaplan-Meier法评估无转移时间与:(1)转移灶的定位;(2)颅内复发的发生;(3)多发转移的发生。结果:共检索到157例患者的数据。少突胶质细胞瘤患者从最初诊断到转移扩散的时间为0 - 325个月,星形细胞瘤患者为0 - 267个月。少突胶质细胞瘤和星形细胞瘤患者分别有19%和39%未接受任何辅助治疗。最常见的转移部位是骨、骨髓和淋巴结。肺和肝是最常受累的内脏部位。多发转移的发生与辅助化疗/放疗的使用无显著相关性。颅内复发/转移的患者与没有任何中枢神经系统内扩散的神经外转移患者相比,神经外转移的无转移时间明显更长。结论:长时间的随访不能排除神经外转移的存在。因此,骨和颈部淋巴结的靶向成像可以提高这些供体管理的安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
364
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信